Warning: The NCBI web site requires JavaScript to function. more...
Designing a HER2/neu promoter to drive alpha1,3galactosyltransferase expression for targeted anti-alphaGal antibody-mediated tumor cell killing.
Lanteri M, Ollier L, Giordanengo V, Lefebvre JC.
Breast Cancer Res. 2005;7(4):R487-94. Epub 2005 May 3.
Related citations
Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA, Vellon L, Lupu R.
Ann Oncol. 2005 Aug;16(8):1253-67. Epub 2005 May 3.
Decrease of human pancreatic cancer cell tumorigenicity by alpha1,3galactosyltransferase gene transfer.
Aubert M, Crotte C, Bernard JP, Lombardo D, Sadoulet MO, Mas E.
Int J Cancer. 2003 Dec 20;107(6):910-8.
Expression of xenoantigen transformed human cancer cells to be susceptible to antibody-mediated cell killing.
Yoshimura N, Sawada T, Furusawa M, Fuchinoue S.
Cancer Lett. 2001 Mar 26;164(2):155-60.
HER2 (erbB-2)-targeted effects of the omega-3 polyunsaturated fatty acid, alpha-linolenic acid (ALA; 18:3n-3), in breast cancer cells: the "fat features" of the "Mediterranean diet" as an "anti-HER2 cocktail".
Menéndez JA, Vázquez-Martín A, Ropero S, Colomer R, Lupu R.
Clin Transl Oncol. 2006 Nov;8(11):812-20.
A genomic explanation connecting "Mediterranean diet", olive oil and cancer: oleic acid, the main monounsaturated fatty acid of olive oil, induces formation of inhibitory "PEA3 transcription factor-PEA3 DNA binding site" complexes at the Her-2/neu (erbB-2) oncogene promoter in breast, ovarian and stomach cancer cells.
Menendez JA, Papadimitropoulou A, Vellon L, Lupu R.
Eur J Cancer. 2006 Oct;42(15):2425-32. Epub 2006 Jan 6.
Mediterranean dietary traditions for the molecular treatment of human cancer: anti-oncogenic actions of the main olive oil's monounsaturated fatty acid oleic acid (18:1n-9).
Menendez JA, Lupu R.
Curr Pharm Biotechnol. 2006 Dec;7(6):495-502. Review.
Relationship between alphaGal epitope expression and decrease of tumorigenicity in pancreatic adenocarcinoma model.
Aubert M, Crotte C, Benkoel L, Panicot-Dubois L, Bernard JP, Lombardo D, Sadoulet MO, Mas E.
Mol Carcinog. 2005 Apr;42(4):202-12.
DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.
Int J Mol Med. 2006 Dec;18(6):1081-7.
Glycoengineering of alphaGal xenoantigen on recombinant peptide bearing the J28 pancreatic oncofetal glycotope.
Sadoulet MO, Franceschi C, Aubert M, Silvy F, Bernard JP, Lombardo D, Mas E.
Glycobiology. 2007 Jun;17(6):620-30. Epub 2007 Mar 20.
Targeting HER2: recent developments and future directions for breast cancer patients.
Wang SC, Zhang L, Hortobagyi GN, Hung MC.
Semin Oncol. 2001 Dec;28(6 Suppl 18):21-9. Review.
Re-expression of SPR1 in breast cancer cells by phorbol 12-myristate 13-acetate (PMA) or UV irradiation is mediated by the AP-1 binding site in the SPR1 promoter.
Anisowicz A, Sotiropoulou G, Sager R.
Mol Med. 1999 Aug;5(8):526-41.
PEA3 cooperates with c-Jun in regulation of HER2/neu transcription.
Matsui K, Sugimori K, Motomura H, Ejiri N, Tsukada K, Kitajima I.
Oncol Rep. 2006 Jul;16(1):153-8.
Binding of an ETS-related protein within the DNase I hypersensitive site of the HER2/neu promoter in human breast cancer cells.
Scott GK, Daniel JC, Xiong X, Maki RA, Kabat D, Benz CC.
J Biol Chem. 1994 Aug 5;269(31):19848-58.
Xenoantigen, an alphaGal epitope-expression construct driven by the hTERT-promoter, specifically kills human pancreatic cancer cell line.
Sawada T, Yamada O, Yoshimura N, Hatori K, Fuchinoue S, Teraoka S.
Cancer Cell Int. 2002 Oct 3;2(1):14.
Xenotransplantation and ABO incompatible transplantation: the similarities they share.
Galili U.
Transfus Apher Sci. 2006 Aug;35(1):45-58. Epub 2006 Aug 14. Review.
A new vector for controllable expression of an anti-HER2/neu mini-antibody-barnase fusion protein in HEK 293T cells.
Glinka EM, Edelweiss EF, Sapozhnikov AM, Deyev SM.
Gene. 2006 Jan 17;366(1):97-103. Epub 2005 Nov 21.
The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2.
Jäger M, Schoberth A, Ruf P, Hess J, Lindhofer H.
Cancer Res. 2009 May 15;69(10):4270-6. Epub 2009 May 12.
HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer.
Benz CC, O'Hagan RC, Richter B, Scott GK, Chang CH, Xiong X, Chew K, Ljung BM, Edgerton S, Thor A, Hassell JA.
Oncogene. 1997 Sep 25;15(13):1513-25.
An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2.
Wright M, Grim J, Deshane J, Kim M, Strong TV, Siegal GP, Curiel DT.
Gene Ther. 1997 Apr;4(4):317-22.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on